Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-03-27
1999-04-06
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514309, 514312, 514345, 514361, 514401, 514406, 514518, 514530, 514567, 514632, 546141, 546172, 546290, 548127, 5483531, 5483671, 549230, 558 56, 560303, 562431, 562432, 564228, A61K 31155, A61K 31255, C07C28118, C07C30973
Patent
active
058919090
ABSTRACT:
Amidino and benzamidino compounds, including compounds of the formula: ##STR1## wherein R.sup.1 -R.sup.4, R.sup.6 -R.sup.9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.
REFERENCES:
patent: 3271448 (1966-09-01), Augstein et al.
patent: 4226885 (1980-10-01), Orzalesi et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4665085 (1987-05-01), Coquelet et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4764604 (1988-08-01), Muller
patent: 4824849 (1989-04-01), Baldwin et al.
patent: 5024998 (1991-06-01), Bodor
patent: 5296498 (1994-03-01), Malen et al.
patent: 5466811 (1995-11-01), Alexander
Campi et al., Aust. J. Chem., 49, 219-230 (1996).
Baugh, R.J., and Travis, J., "Human Leukocyte Granule Elastase: Rapid Isolation and Characterization," Biochemistry 15(4):836-841 (1976).
Cleason, G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," Blood Coagulation and Fibrinolysis 5:411-436 (1994).
Corey, E.J., and Schmidt, G., "Useful Procedures for the Oxidation of Alcohols Involving Pyridinium Dichromate in Aprotic Media," Tetrahedron Lett. 5:399-402 (1979).
Corey, E.J., and Suggs, J.W., "Pyridinium Chlorochromate. An Efficient Reagent for Oxidation of Primary and Secondary Alcohols to Carbonyl Compounds," Tetrahedron Lett. 31:2647-2650 (1975).
Coughlin, S.R., "Molecular Mechanisms of Thrombin Sighnaling," Seminars in Hematology 31(4):270-277 (1994).
Cuypers, H.T., et al., "Sulfhydryl Content of Bovine Eye Lens Leucine Aminopeptidase," J. Biol. Chem. 257(12):7086-7091 (1982).
Godfrey, J.D., Jr., et al., "Synthesis of Peptide Derived Amino Alcohols II. Synthetic Methodology for the Preparation of Tertiary Alcohols," Tetrahedron Lett. 28(15):1603-1606 (1987).
Harker, L.A., "Strategies for Inhibiting the effects of thrombin," Blood Coagulation and Fibrinolysis 5(Suppl. 1):S47-S58 (1994).
Lefkovits, J., and Topol, E.J., "Direct Thrombin Inhibitors in Cardiovascular Medicine," Circulation 90(3):1522-1536 (1994).
Notari, R.E., "Theory and Practice of Prodrug Kinetics," Methods in Enzymology 112:309-323 (1985).
Sauliner, M.G., et al., "An Efficient Method for the Synthesis of Guanidino Prodrugs," Bioorg. & Medicinal Chem. Lett. 4(16):1985-1990 (1994).
Tapparelli, C., et al., "Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacologial profile," Trends in Pharm. Sci. 14:366-376 (1993).
English language abstract of German Patent No, 1 263 762 (Document AL1), Chemical Abstracts 69(17):6325-6326 (Abstract 67624z) (1968).
Ackerley, N. et al., "A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antogonists and -Thromboxane Synthesis Inhibitors," Chem. Abst. 123(21):34 (Abstract No. 275234) (1995).
Mizuno, K. et al., "Studies on antidiabetic agents. V. Synthesis of the metabolites of 5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidione (CT-112) and related compounds," Chem. Abst. 101(7):612 (abstract No. 54974) (1984). phenoxy)alkyl!acetohydroxamic acids, potential inhibitors of the enzyme 5-lipoxygenase," Chem. Abtr. 116(13)824 (Abstract No. 128264) (1992).
Fedde Cynthia L.
Illig Carl
Lu Tianbao
Soll Richard M.
Tomczuk Bruce E.
3-Dimensional Pharmaceuticals Inc.
Oswecki Jane C.
Richter Johann
LandOfFree
Amidinohydrazones as protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amidinohydrazones as protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amidinohydrazones as protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371769